title: [Treatment of aspirin resistance patients at transient ischemic attack by buyang huanwu decoction combination with aspirin: a randomized control observation].
abstract: OBJECTIVE
  To investigate the curative effect and safety of buyang huanwu decoction (BHD) combined aspirin (ASP) in treatment of aspirin resistance (AR) patients at transient ischemic attack (TIA).
  
  
  METHODS
  Recruited were 86 AR patients at TIA who took ASP as the secondary prevention. Two cases were rejected due to poor compliance. The rest 84 patients were randomly assigned to the treatment group and the control group. Those in the treatment group were treated with BHD and ASP, while those in the control group took Clopidogrel and ASP. After 30-, 60-, and 90-day of treatment, arachidonic acid (AA) and adenosine diphosphate (ADP) induced platelet aggregation rate (PAG) were detected using turbidimetry. After treatment of 90 days, the case numbers of TIA recurrence or of progressing to cerebral infarction were counted. The incidence of adverse events was also observed.
  
  
  RESULTS
  The ADP-and AA-induced PAG showed similar decreasing tendency in the treatment group and the control group at each time point (P >0.05). There was no statistical difference in the risk control of end point events (including ischemic cerebrovascular diseases, TIA recurrence, cerebral infarction) between the two groups (P >0.05). One patient suffered from bleeding (mild gastrointestinal bleeding) in the treatment group, while 4 patients suffered from bleeding (3 due to skin and mucous membrane bleeding and 1 to stool bleeding). The bleeding risk was lowered by 76.29% in the treatment group when compared with the control group.
  
  
  CONCLUSIONS
  BHD combined ASP showed similar efficacy in treating AR and controlling endpoint events. Besides, they lowered bleeding risk.
authors.affiliation: Traditional Chinese Medicine Hospital of Xinjiang Uyghur Autonomous Region, Urumqi 830000, China. zhang30lei@tom.com
authors.forename: Lei
authors.initials: L
authors.lastname: Zhang
authors.forename: Tao
authors.initials: T
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use*; D004351:Drug Resistance; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D004365:Drugs, Chinese Herbal; C460102:buyang huanwu; D001241:Aspirin